Companies:64525
FatCapitalist:Apple Inc. [AAPL]United States

Cytokinetics, Incorporated [CYTKUnited States

NasdaqGS exchange. Sector: Healthcare. Industry: Biotechnology. Location United States, South San Francisco.
At close Fri Sep 30 2022
48.45 USD 👎0.78 (-1.61%)

At close Fri Sep 30 2022

Marketcap
4,088,893,952 USD

Marketcap

PE:.
BETA (5y):1.176
EPS:-1.973
Profits

for 5 years

386%

for 3 years

622%

for 2 years

313%

for 1 year

158%

for this year

53%
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.

Cytokinetics, Incorporated
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.